One Dose of HPV Vaccine Noninferior to Two: Implications for Global Cervical Cancer Prevention
Highlights
– A large randomized trial (ESCUDDO; NCT03180034) compared one versus two doses of bivalent and nonavalent HPV vaccines in girls 12–16 years and found one dose was noninferior to two doses for preventing persistent HPV16/18 infection over 5 years.
– Rate differences between one and two doses were small and within the prespecified noninferiority margin (bivalent: -0.13 per 100; nonavalent: 0.21 per 100). Vaccine effectiveness relative to an unvaccinated survey exceeded 97% in each group.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.